On-Demand Recording | Earn 1.5 CME Credits
A New Era in Solid Tumor Therapy
CAR T-cell therapy has transformed the treatment landscape for hematologic malignancies, yet its application in solid tumors has long been limited by complex biological barriers. The tumor microenvironment can suppress immune activity, while CAR T cells often face challenges in expansion, persistence, and sustained anti-tumor function. These obstacles have driven a new wave of innovation aimed at unlocking the full therapeutic potential of CAR T-cell therapy in solid tumors.
We are pleased to share the recording of this groundbreaking webinar, delivered in collaboration with the International Conference on Lymphocyte Engineering (ICLE). The session explores how CAR T-cell therapy is evolving to overcome key barriers in solid tumor treatment.
This interactive scientific discussion examines the latest advances in GPC3-targeted CAR T-cell therapy across both pediatric and adult solid tumors, highlighting pioneering research that is shaping next-generation treatment strategies.
Register or log in to the UNLOKall portal to access the recording.
Join UNLOKall in 3 Steps:
- Select Multidisciplinary Academy on the registration page
- Complete your registration with our secure chat bot
- Log in and start exploring!
What You’ll Learn
- How CAR T-cell therapy is evolving beyond hematologic cancers
- The role of GPC3 targeting in solid tumor treatment
- Breakthrough strategies using cytokine-armored CAR T cells
- How co-expression of IL-15 and IL-21 enhances T-cell fitness, proliferation, and durability
- Real-world insights from leading experts in pediatric oncology and immunotherapy
Speakers
Dr. David Steffin
Associate Chief and Inpatient Medical Director of Pediatric Blood and Marrow Transplantation at Texas Children’s Hospital and Baylor College of Medicine. He specializes in CAR T-cell therapies for pediatric solid tumors, addressing the unique challenges these cancers present. His research has been published widely and informs cutting-edge approaches in immunotherapy.
Moderator
Prof. Dinorah Friedmann-Morvinski
Associate Professor at Tel Aviv University, studies tumor plasticity and the tumor microenvironment in pediatric and adult brain cancers. Her lab develops innovative CAR T-cell and nanomedicine therapies to overcome tumor resistance and improve patient outcomes.